Treatment of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction

References

• Aktas BK, Gokkaya CS, Bulut S, et al. Impact of metabolic syndrome on erectile dysfunction and lower urinary tract symptoms in benign prostatic hyperplasia patients. Aging Male. 2011;14:48–52.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Lee JY, O’Neill EA, et al. Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male. 2013;16:169–172.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, O'Neill E, Lowe R, et al. Prevalence of low testosterone in aging men with benign prostatic hyperplasia: data from the Proscar Long-term Efficacy and Safety Study (PLESS). Aging Male. 2013;16:48–51.
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19:64–69.
   PubMed Web of Science ®Google Scholar
• Haider KS, Haider A, Doros G, et al. Long-term testosterone therapy improves urinary and sexual function, and quality of life in men with hypogonadism: results from a propensity matched subgroup of a controlled registry study. J Urol. 2018;199:257–265.
   PubMed Web of Science ®Google Scholar
• Kaufman JM. The effect of androgen supplementation therapy on the prostate. Aging Male. 2003;6:166–174.
   PubMedGoogle Scholar
• Singam P, Hong GE, Ho C, et al. Nocturia in patients with benign prostatic hyperplasia: evaluating the significance of ageing, co-morbid illnesses, lifestyle and medical therapy in treatment outcome in real life practice. Aging Male. 2015;18:112–117.
   PubMed Web of Science ®Google Scholar
• Besiroglu H, Dursun M, Otunctemur A, et al. The association between triglyceride high density lipoprotein cholesterol ratio and benign prostate hyperplasia in non-diabetic patients: a cross-sectional study. Aging Male. 2017;23:1–7.
   Web of Science ®Google Scholar
• Arivazhagan J, Nandeesha H, Dorairajan LN, et al. Association of elevated interleukin-17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia. Aging Male. 2017;20:115–118.
   PubMed Web of Science ®Google Scholar
• Park SG, Yeo JK, Cho DY, et al. Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia. Aging Male. 2017;17:1–5.
   Web of Science ®Google Scholar
• Ren H, Li X, Cheng G, et al. The effects of ROS in prostatic stromal cells under hypoxic environment. Aging Male. 2015;18:84–88.
   PubMed Web of Science ®Google Scholar
• Ferreira FT, Daltoé L, Succi G, et al. Relation between glycemic levels and low tract urinary symptoms in elderly. Aging Male. 2015;18:34–37.
   PubMed Web of Science ®Google Scholar
• Ohwaki K, Endo F, Shimbo M, et al. Comorbidities as predictors of incidental prostate cancer after Holmium laser enucleation of the prostate: diabetes and high-risk cancer. Aging Male. 2017;23:1–4.
   Web of Science ®Google Scholar
• Asiedu B, Anang Y, Nyarko A, et al. The role of sex steroid hormones in benign prostatic hyperplasia. Aging Male. 2017;20:17–22.
   PubMed Web of Science ®Google Scholar
• Allen S, Aghajanyan I. Use of thermobalancing therapy in ageing male with benign prostatic hyperplasia with a focus on etiology and pathophysiology. Aging Male. 2017;20:28–32.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Fujimura T, Nagata M, et al. Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and International Index of Erectile Function-5 questionnaires. Aging Male. 2012;15:111–114.
   PubMed Web of Science ®Google Scholar
• Guzelsoy M, Aydos MM, Coban S, et al. Comparison of the effectiveness of IPSS and VPSS without any help in LUTS patients: a prospective study. Aging Male. 2017;11:1–7.
   Web of Science ®Google Scholar
• Coban S, Doluoglu OG, Keles I, et al. Age and total and free prostate-specific antigen levels for predicting prostate volume in patients with benign prostatic hyperplasia. Aging Male. 2016;19:124–127.
   PubMed Web of Science ®Google Scholar
• Pajovic B, Radojevic N, Dimitrovski A, et al. The therapeutic potential of royal jelly in benign prostatic hyperplasia. Comparison with contemporary literature. Aging Male. 2016;19:192–196.
   PubMed Web of Science ®Google Scholar
• Li A, Lu H, Liu S, et al. Effect of ageing on the efficacy efficiency of TUVRP. Aging Male. 2012;15:263–266.
   PubMed Web of Science ®Google Scholar
• Gu X, Strom K, Spaliviero M, et al. Does age affect the efficacy and safety of GreenLight HPS™ laser photoselective vaporization prostatectomy? Aging Male. 2012;15:63–67.
   PubMed Web of Science ®Google Scholar
• Liatsikos E, Kyriazis I, Kallidonis P, et al. Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options. Aging Male. 2011;14:141–149.
   PubMed Web of Science ®Google Scholar
• Bardoli AD, Taylor WSJ, Mahmalji W. Can the UroLift prostatic implant device treat the symptoms of benign prostatic hypertrophy, avoid sexual dysfunction and reduce hospital TURP waiting times? A single centre, single surgeon experience and review of the literature. Aging Male. 2017;13:1–6.
   Web of Science ®Google Scholar
• Qian X, Liu H, Xu D, et al. Functional outcomes and complications following B-TURP versus HoLEP for the treatment of benign prostatic hyperplasia: a review of the literature and meta-analysis. Aging Male. 2017;3:1–8.
   Web of Science ®Google Scholar
• Amano T, Earle C, Imao T, et al. Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia. Aging Male. 2017;22:1–6.
   Web of Science ®Google Scholar
• Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61:994–1003.
   PubMed Web of Science ®Google Scholar
• Dong Y, Hao L, Shi Z, et al. Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis. Urol Int. 2013;91:10–18.
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Roehrborn C, Klise S, et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol. 2010;183:1092–1097.
   PubMed Web of Science ®Google Scholar
• Porst H, Roehrborn CG, Secrest RJ, et al. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies. J Sex Med. 2013;10:2044–2052.
   PubMed Web of Science ®Google Scholar
• Park HJ, Won J, Sorsaburu S, et al. Urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: a systematic review focusing on tadalafil. World J Mens Health. 2013;31:193–207.
   PubMedGoogle Scholar
• Kolontarev K, Govorov A, Kasyan G, et al. Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors. Cent European J Urol. 2016;69:398–403.
   PubMed Web of Science ®Google Scholar
• Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol. 2004;172:1935–1940.
   PubMed Web of Science ®Google Scholar
• Giuliano F, Kaplan SA, Cabanis MJ, et al. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology. 2006;67:1199–1204.
   PubMed Web of Science ®Google Scholar
• Singh DV, Mete UK, Mandal AK, et al. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. J Sex Med. 2014;11:187–196.
   PubMed Web of Science ®Google Scholar
• Liguori G, Trombetta C, De Giorgi G, et al. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med. 2009;6:544–552.
   PubMed Web of Science ®Google Scholar
• Sairam K, Kulinskaya E, McNicholas TA, et al. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90:836–839.
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Guhring P, Parker M, et al. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med. 2006;3:662–667.
   PubMed Web of Science ®Google Scholar
• McVary KT, Monnig W, Camps JL Jr, et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007;177:1071–1077.
   PubMed Web of Science ®Google Scholar
• Ko WJ, Han HH, Ham WS, et al. Daily use of sildenafil 50mg at night effectively ameliorates nocturia in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: an exploratory multicenter, double-blind, randomized, placebo-controlled study. Aging Male. 2017;20:81–88.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007;51:1717–1723.
   PubMed Web of Science ®Google Scholar
• Tuncel A, Nalcacioglu V, Ener K, et al. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol. 2010;28:17–22.
   PubMed Web of Science ®Google Scholar
• Gülcer C, Tüzel E, Dogantekin E, et al. Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement? Urol Int. 2008;80:181–185.
   PubMed Web of Science ®Google Scholar
• Guven EO, Balbay MD, Mete K, et al. Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. Int Urol Nephrol. 2009;41:287–292.
   PubMed Web of Science ®Google Scholar
• Alwaal A, Al-Mannie R, Carrier S. Future prospects in the treatment of erectile dysfunction: focus on avanafil. Drug Des Devel Ther. 2011;5:435–443.
   PubMed Web of Science ®Google Scholar
• Stief C, Porst H, Neuser D, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008;53:1236–1244.
   PubMed Web of Science ®Google Scholar
• Wang R, Burnett AL, Heller WH, et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med. 2012;9:2122–2129.
   PubMed Web of Science ®Google Scholar
• Smith-Harrison LI, Patel A, Smith RP. The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction. Transl Androl Urol. 2016;5:181–186.
   PubMed Web of Science ®Google Scholar
• Lee JY, Cho SY, Oh CY, et al. Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study. Int J Impot Res. 2011;23:249–256.
   PubMed Web of Science ®Google Scholar
• Cho MC, Paick JS. A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction. Ther Adv Urol. 2016;8:100–117.
   PubMed Web of Science ®Google Scholar
• Chung BH, Lee JY, Lee SH, et al. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res. 2009;21:122–128.
   PubMed Web of Science ®Google Scholar
• Kosilov K, Kuzina I, Kuznetsov V, et al. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage. Aging Male. 2017;7:1–9.
   Web of Science ®Google Scholar
• Henningsohn L, Kilany S, Svensson M, et al. Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an α-blocker in men with overactive bladder in Sweden: a non-interventional study. Aging Male. 2017;20:266–276.
   PubMed Web of Science ®Google Scholar
• Lin KH, Lin YW, Wen YC, et al. Efficacy and safety of orally disintegrating tamsulosin tablets in Taiwanese patients with benign prostatic hyperplasia. Aging Male. 2012;15:246–252.
   PubMed Web of Science ®Google Scholar
• Qian X, Yu G, Qian Y, et al. Efficacy of 5α-reductase inhibitors for patients with large benign prostatic hyperplasia (>80 mL) after transurethral resection of the prostate. Aging Male. 2015;18:238–243.
   PubMed Web of Science ®Google Scholar
• Salah Azab S, Elsheikh MG. The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS. Aging Male. 2015;18:89–92.
   PubMed Web of Science ®Google Scholar
• Comhaire F, Mahmoud A. Preventing diseases of the prostate in the elderly using hormones and nutriceuticals. Aging Male. 2004;7:155–169.
   PubMedGoogle Scholar
• Favilla V, Russo GI, Privitera S, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male. 2016;19:175–181.
   PubMed Web of Science ®Google Scholar